Skip to main content

Target Validation in Drug Discovery

  • 1st Edition - September 22, 2006
  • Editors: Brian W. Metcalf, Susan Dillon
  • Language: English
  • Hardback ISBN:
    9 7 8 - 0 - 1 2 - 3 6 9 3 9 3 - 8
  • eBook ISBN:
    9 7 8 - 0 - 0 8 - 0 4 6 5 9 7 - 5

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies,… Read more

Target Validation in Drug Discovery

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Book bundle cover eBook and print

Institutional subscription on ScienceDirect

Request a sales quote
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.